Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer

Chest

Volumn 115, Issue 3, 1999, Pages 901-905

  Folz, Rodney J ^a   Elkordy, Maha A ^a  

^a NONE

Author keywords

Bone marrow transplantation; Breast cancer; Coronavirus pneumonia; High dose chemotherapy; Idiopathic pneumonia syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROMYCIN; FLUOROURACIL; IMIPENEM; METHYLPREDNISOLONE; PREDNISONE;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CORONAVIRUS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ELECTRON MICROSCOPY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG LAVAGE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THORAX RADIOGRAPHY; VIRUS PNEUMONIA;

EID: 0032995664     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.3.901     Document Type: Article

References (31)

1. 1 Weiner RS, Boymer MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986; 104:168-175
2. 2 Wingard JR, Mellits ED, Sostrin MB, et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Medicine 1988; 67:175-186
3. 3 Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85:640-647
4. 4 Clark JG, Hansen JA, Hertz MI, et al. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147:1601-1606
5. 5 Cherniack RM, Abrams J, Kalica AR. Pulmonary disease associated with breast cancer therapy. Am J Respir Crit Care Med 1994; 150:1169-1173
6. 6 Wilczynski SW, Erasmus JJ, Petros WP, et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998; 157:565-573
7. 7 Wilczynski SW, Petros WP, Hussein AM, et al. Increased incidence of pulmonary toxicity in breast cancer patients undergoing high dose chemotherapy. Am J Respir Crit Care Med 1996; 153:A273
8. 8 Patz EF Jr, Peters WP, Goodman PC. Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. J Thorac Imaging 1994; 9:129-134
9. 9 Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. N Engl J Med 1980; 303:183-188
10. 10 Rabinowitz J, Petros WP, Stuart AR, et al. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 1993; 81:2452-2459
11. 11 Murase T, Anscher MS, Petros WP, et al. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity. Bone Marrow Transplant 1994; 15:173-178
12. 12 Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Int Med 1988; 109:203-208
13. 13 Fouillard L, Mouthon L, Laporte JP, et al. Sever respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992; 9:97-100
14. 14 Smith AC, Boyd MR. Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity. J Pharmacol Exp Ther 1984; 229:658-663
15. 15 Kaye HS, Marsh HB, Dowdle WR. Seroepidemiologic survey of coronavirus (strain OC43) related infections in a children's population. Am J Epidemiol 1971; 94:43-49
16. 16 Hendley JO, Fishburne HB, Gwaltney JM. Coronavirus infections in working adults: eight year study with 229E and OC43. Am Rev Respir Dis 1972; 105:805-811
17. 17 Hamre D, Beem M. Virologic studies of acute respiratory disease in young adults: V. Coronavirus 229E infections during 6 years of surveillance. Am J Epidemiol 1972; 96:94-106
18. 18 McIntosh K, Chao RK, Krause HE, et al. Coronavirus infection in acute lower respiratory tract disease of infants. J Infect Dis 1974; 130:502-507
19. 19 Wenzel RP, Hendley JO, Davies JA, et al. Coronavirus infections in military recruits. Am Rev Respir Dis 1974; 109:621-624
20. 20 Riski H, Hovi T. Coronavirus infections of man associated with diseases other than the common cold. J Med Virol 1980; 6:259-265
21. 21 Todd NW, Peters WP, Ost AH, et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993; 147:1264-1270
22. 22 Fulkerson WJ, McLendon RE, Prosnitz LR. Adult respiratory distress syndrome after limited thoracic radiotherapy. Cancer 1986; 57:1941-1946
23. 23 Bhatt PN, Jacoby R, Jonas AM. Respiratory infection in mice with sialodacryoadenitis virus, a coronavirus of rats. Infect Immun 1977; 18:823-827
24. 24 Jabrane A, Girard C, Elazhary Y. Pathogenicity of porcine respiratory coronavirus isolated in Quebec. Can Vet J 1994; 35:86-92
25. 25 Bradburne AF, Bynoe ML, Tyrrell DAJ. Effects of a 'new' human respiratory virus in volunteers. BMJ 1967; 3:767-769
26. 26 Reed SE. The behavior of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains. J Med Virol 1984; 13:179-192
27. 27 Bende M, Barrow I, Heptonstall J, et al. Changes in human nasal mucosa during experimental coronavirus common colds. Acta Otolaryngol (Stockh) 1989; 107:262-269
28. 28 Higgins PG, Phillpotts RJ, Scott GM, et al. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24:713-715
29. 29 Turner RB, Felton A, Kosak K, et al. Prevention of experimental coronavirus colds with intranasal α-2b interferon. J Infect Dis 1986; 154:443-447
30. 30 Barrow GI, Higgins PG, Al-Nakib W, et al. The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers. Clin Exp Allergy 1990; 20:45-51
31. 31 American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Am J Respir Crit Care Med 1995; 152:2185-2198